1 / 42

January 8, 2009 Antiretroviral Treatment of HIV-1 Infected Children Lisa Frenkel, MD

January 8, 2009 Antiretroviral Treatment of HIV-1 Infected Children Lisa Frenkel, MD. Antiretroviral Treatment of HIV-1 Infected Children Lisa M. Frenkel, MD Professor of Pediatrics and Laboratory Medicine University of Washington and Seattle Children's Hospital

holli
Download Presentation

January 8, 2009 Antiretroviral Treatment of HIV-1 Infected Children Lisa Frenkel, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. January 8, 2009 Antiretroviral Treatment of HIV-1 Infected Children Lisa Frenkel, MD

  2. Antiretroviral Treatment of HIV-1 Infected Children Lisa M. Frenkel, MD Professor of Pediatrics and Laboratory Medicine University of Washington and Seattle Children's Hospital email: lfrenkel@u.washington.edu

  3. Case 1: A woman brings her 7 month old infant “baby girl” to clinic because the baby is breathing rapidly. During pregnancy the mother was followed in your clinic and her HIV EIA was (-) at 28 weeks gestation. She has been breastfeeding her child. “Baby girl” has had routine immunizations. She does not have rhinorrhea, vomiting or diarrhea. She does not have a fever, rales, rhochi or wheezes, but her respiratory rate is 78 breathes/minute. • What is the differential diagnosis? • What tests do you recommend? • What empiric treatment do you provide?

  4. Case 1: 7 month old “baby girl” with no fever, rales, rhochi or wheezes.Respiratory rate is 68 breaths/minute. • What is the differential diagnosis? • Pneumocyctis pneumonia • Acute bronchospasm • Acidosis • What tests do you recommend? • HIV-1 rapid serology of mother • HIV-1 DNA, RNA or p24Ag of baby • Chest x-ray • Sputum for Pneumocystis jirovecii • direct immunofluorescence assay (DFA) • PCR • What empiric treatment do you provide? • Co-trimoxazole • Dapsone • Atovaquone

  5. Maternal blood cells and HIV do not cross a healthy placenta, but the mother’s antibodies cross • Maternal HIV antibodies persist in infant for 18 months • HIV EIA (+) even when uninfected • Definitive diagnosis • Polymerase chain reaction (PCR) amplification of HIV DNA or RNA • Core HIV protein (p24Ag) • Presumptive diagnosis • Maternal antibodies & an ill infant

  6. Teaching Point -- Case 1: “baby girl” with pneumocystis pneumonia (AIDS) infected by mother with acute, asymtomic HIV infection • HIV-1 infection of women in late gestation or during breastfeeding frequently is transmitted to their infants either in utero or via breast milk • Communities with a high incidence HIV-1 should repeat HIV testing in late gestation • Women not tested during gestation should receive rapid HIV testing in labor • Interventions can decrease mother-to-child-transmission: • Antiretroviral prophylaxis of fetus in utero and infant after birth • Elective Cesarean • Exclusive breastfeeding • Artificial feeding • HIV PCR or p24Ag are needed for accurate early diagnosis, however, when unavailable empiric treatment should be based on clinical diagnosis

  7. Access to HIV-1 Testing during Gestation and to Antiretrovirals to Reduce Mother-to-Child-Transmission Varies but is Improving

  8. Acess to Antiretrovirals to Reduce Mother-to-Child-Transmission Varies but is Improving

  9. MAJOR ISSUE:Multiple impediments to HIV-1 testing during gestation and to antiretrovirals to reduce mother-to-child-transmission in resource-poor communities • Women do not access prenatal care • HIV testing not offered as part of routine obstetrical care • Insufficient time for testing, CD4 counts and initiation of antiretrovirals • Stigma associated with HIV testing and interventions, ART and artificial infant feeding

  10. Teaching Point -- Case 1: “Baby girl” with pneumocystis pneumonia (AIDS), infected by mother with acute, asymtomic HIV infection • Pneumocystis pneumonia is common in HIV infected infants not • receiving prophylaxis • Pneumocystis jirovecii • an ubiquitous fungus • infects most infants - immunocompromised become ill • slow growing - prophylaxis is effective when begun at 4 - 6 weeks of age • HIV infected infants should receive prophylaxis until 5 years old, or CD4 counts above threshold for safely stopping prophylaxis • DFA and PCR on induced sputa are very sensitive, however, when unavailable empiric treatment should be based on clinical diagnosis • Co-trimoxazole is the most effective prophylaxis and treatment • Corticosteroids may improve outcome of severe cases

  11. Case 2: • A HIV infected woman brings her 7 day old infant “baby boy” to clinic. He appears healthy, and is breastfeeding well. • You check the baby’s HIV DNA/RNA test from the day of birth. • His “birth” HIV DNA/RNA is (-). The mother asks you for advice to keep “baby boy” free of HIV infection. • What do you recommend?

  12. HIV infection in infants between 0-24 months after randomized to nevirapine vs. nevirapine/zidovudine vs. placebo • for 14 weeks after birth • NI Kumwenda et al. NEJM 2008; 359 : 119-29.

  13. Case 1 and 2 -- continued: The mother chose daily nevirapine prophylaxis for her “baby boy”. He is clinically well, however a HIV DNA PCR is (+) when he is 2.5 months old. The “baby girl” you treated for pneumocystis improves with a 3 week course of co-trimoxazole.Both the “baby boy” and the “baby girl” are in your clinic today. The boy is now 3 and girl 10 months old. • What do you recommend?

  14. Children, mean 4.7 years Incidence AIDS 0 5 10 15 Years since HIV-1 infection Clinical course of HIV infection in children can be “rapid” or “slow” D Dunn et al. J Infect Dis 2008:197:398–404

  15. When to start ART in Infants/Children - WHO focus • Presumptive diagnosis - when PCR unavailable - Seropositive + severe symptoms - oral thrush - severe pneumonia - severe sepsis - Severe maternal disease (%CD4<20), AIDS or death 2. At time of infant diagnosis by HIV PCR or p24Ag (+) • ~40% HIV-1 infants die in first 1 years of life (Dabis, AIDS 2001;15:771; Fassinou, AIDS 2004;18:1905; Newell, Lancet 2004;364:1236; Brahmbhatt JAIDS 2006;41:504) • ART successful and non-toxic (Luzuriaga, NEJM 2004;350:2471) • If start ART early, should ART be stopped later when CD4 normal? 3. Clinical symptoms - Stages 3 and 4, and 1 and 2 if low CD4 4. Immunologic status - Low CD4 for age 5. Family/Caregiver “ready” • Understand life-long therapy • Able to adhere to prescribed regimen - gastrostomy tubes • Can store and administer liquids • Teach child to swallow pills

  16. When to start ART - WHO Clinical Stages 1-4 • Asymptomatic or persistent generalized lymphadenopathy • Mild clinical symptoms • Persistent hepato-splenomegally • Papular pruritic eruptions • Fungal infections • Cheilitis • Linear gingival erythema • Extensive papilomas or molluscum • Herpes zoster • Recurrent upper respiratory tract infections • Moderate clinical symptoms • Malnutrition • Persistent diarrhea or recurrent fever • Thrush or leukoplakia • Lymph node or pulmonary TB, • Recurrent bacterial pneumonias • Lymphocytic interstitial pneumonitis • Necrotizing gingivitis

  17. When to start ART - WHO Clinical Stages 1-4 4. Severe clinical symptoms • Severe wasting - stunted growth • Pneumocystis pneumonia • Recurrent severe bacterial infections • Chronic HSV >1 month • Extrapulmonary TB • Esophageal candidiasis • Kaposi sarcoma • CMV retinitis, colitis • CNS Toxoplasmosis • Extrapulmonary cryptococcosis • HIV encephalopathy • Disseminated mycosis • Disseminated non-TB mycobacteria • Chronic cryptosporidiosis • Chronic Isospora • Cerebral or B cell non-Hodgkin lymphoma • Progressive multifocal leukoencephalopathy • Symptomatic nephropathy • Symptomatic cardiomyopathy

  18. When to start ART - WHO Immune Parameters • Asymptomatic children - CD4 tests on 2 occasions if sole basis for ART • Immunologic status qualifying for ART without symptoms vary by age • CD4% or absolute CD4 cells • <12mo: <25% or <1500/uL • 12-36mo: <20% or <750/uL • 3-5yo: <15% or <350/uL • >5: <15% or <200/uL • Total lymphocyte count (TLC) • <12mo: <4000/uL • 12-36mo: <3000/uL • 3-5yo: <2500/uL • 5-8yo: <2000/uL

  19. Infants Incidence AIDS 0 5 10 15 Years since in utero/peripartum HIV-1 infection A trial of early ART:Children with HIV Early Anti-retroviral Therapy: CHER • A. Violari, et al. Antiretroviral therapy and mortality among HIV-infected infants. NEJM 2008; 359: 2233-2244

  20. Randomized Trial - When to Start ART in Infants - CHER • HIV-1 infected South African infants 6-12 weeks old - HIV-1 DNA PCR used diagnosed infection - 6-12 week old CD4% >25% randomized to immediate or delayed ART: - antiretroviral therapy (ART) when the CD4% dropped below 20% - immediate ART with a planned interruption at 1 year of age - immediate ART with a planned interruption at 2 years of age - ART – Lopinavir/r + zidovudine+ lamivudine 2. Participants characteristics • Perinatal chemoprophylaxis: • 62% nevirapine • 20% nevirapine + zidovudine • 2% three antiretrovirals • 11% no antiretrovirals • Started ART at median 7.4 weeks old, CD4 35% • Deaths: 20 infants (16%) vs. 10 (4%) after 32 weeks in study • 76% lower death risk (hazard ratio 0.24, 95% CI 0.11 to 0.52, P = 0.002) • A. Violari, et al. Antiretroviral therapy and mortality among HIV-infected infants. NEJM 2008; 359: 2233-2244

  21. CHER Results: Death or CDC stage C or severe B event in infants randomized to early or deferred ART • A. Violari, et al. Antiretroviral therapy and mortality among HIV-infected infants. NEJM 2008; 359: 2233-2244

  22. What antiretroviral therapy (ART) should be used for “baby boy” and “baby girl” in your clinic? • “ART” composed of 2 nucleosides + either a NNRTI (nevirapine or efavirenz) or a protease inhibitor? • Nevirapine is utilized for ART worldwide – due to low cost • Protease inhibitors less available • If use ART that “fails” select for resistant nucleoside • Accumulation of nucleoside mutations diminishes efficacy of ALL ART regimens • What ART do you prescribe?

  23. Efficacy ART (ZDV+3TC+NVP) in Infants Previously Given single-dose Nevirapine (Mashi Trial) Lockman et al. N Engl J Med 2007;356:135 • Infected infants starting ART: • N= 15 sdNVP • N= 15 placebo • CD4<25% or • symptoms, • 2-33 months old (median 8.4) • Difference in Failure Rate: P< 0.001

  24. Efficacy ART (ZDV+3TC+NVP) in Women Previously Given single-dose Nevirapine (Mashi Trial) Lockman et al. N Engl J Med 2007;356:135 • Infected infants starting ART • CD4<25% or • symptoms, • 2-33 (median 8.4 mo) • N= 15 sdNVP • N= 15 placebo • P< 0.001

  25. A. In Utero “Established” Infection Dynamics of NVP resistant HIV-1 Frequency and decay of NVP resistant by timing of HIV-1 infection: B. In Utero “Acute” Infection C. Peripartum Infection Infants’ Age (months) # NVP-resistant / total # infants N= 20/23 (87%) N= 3/9 (33%) N= 8/21 (38%) (7 missing specimens >6 weeks of age)

  26. What antiretroviral therapy (ART) should be used for “baby boy” and “baby girl” in your clinic? • Remembering -- • If use ART that “fails” select for resistant nucleoside • Accumulation of nucleoside mutations diminishes efficacy of ALL ART regimens • CHOOSE ART based on drug-resistance test or history of nevirapine • Nevirapine-ART for “baby girl” • Protease Inhibitor-ART for “boy”

  27. Teaching Point -- Case 1: 8 month old “baby girl” with AIDS Case 2: 3 month old “baby boy” with asymptomatic HIV and history of prolonged exposure to nevirapine

  28. Two Approaches to Management of ART 1. World Health Organization (WHO): - Initiate and modify ART based on clinical disease or CD4 failure - If ART failure in question, plasma HIV-1 RNA >10,000 copies/mL 2. USA Department of Health and Human Services (DHHS) HIV Treatment Guidelines: - Maintain plasma HIV RNA <50 c/mL - Comparison of two cohorts: - NNRTI-ART: 3-month delay until treatment modification - Death HR= 1.23 (95% CI 1.08, 1.40); P = 0.002 - Immune failure HR= 1.21 (95% CI 1.07, 1.36) P = 0.002 - PI-ART: 3-month delay until treatment modification - Death HR= 0.93 (95% CI 0.87, 0.99) P = 0.03 - Immune failure HR= 1.21 = 0.98 (95% CI 0.94, 1.03) P = 0.45 Peterson et al. AIDS 2008;22:2097-2106 

  29. When should ART be started in children 1-5 years old? And, in adults? Not a clear answer………observational studies suggest….

  30. Decreased rate of AIDS when starting ART with higher CD4 cells in cohort study • Phillips AN et al. When should ART for HIV be started? Brit Med J 2007;334:76. • Egger M et al. Prognosis of HIV-1 infected patients starting HAART: a collaborative analysis of prospective studies. Lancet 2002;360:119.

  31. But, is it better to initiate ART earlier? Concerns with starting ART early: - Costly (# person/years ART) - Adherence suboptimal due to: • Toxicities –mild (e.g. head aches); severe (e.g. cardiac) • Psychologic obstacles: • Recognizes diseased state • Lack of disclosure – inconvenient to take medicine - Exhaustion of treatment options – due to drug-resistance Problems with starting ART late: - May be ineffective – higher death rates in the first months of treatment (IRIS?) - Toxicities may be greater ART started when HIV-1 disease is more advanced Now many ARV options. Also, more effective and better tolerated ART. Primary Question: Are the benefits of ART in children and adults greater if started at CD4 >350, 200-350 or >200 c/uL?

  32. Pilot study ongoing by INSIGHT Network • Goal to assess whether patients will enroll into a randomized study assessing when to start therapy • Concerned that biases of patients and health care about when to start ART may compromise a study • Communities currently starting ART at <200 cells/uL are best suited to evaluate “when to start ART” • The multiple new ARV and multiple ongoing trials comparing these, will allow more ART regimens to sequence over a lifetime…………..

  33. Case 3: A 6 year old HIV infected boy has developed spastic paraparesis, thrush, and lost 10 kg over the past few months . His father and mother have AIDS and active tuberculosis (growing in culture, susceptibility testing incomplete). On a chest x-ray your patient has bilateral pulmonary disease, and his sputum has acid-fast bacilli. • You initiate: • Isoniazid • Rifampicin • Pyrazinamide • Ethambutol • Pyridoxine • Do you start ART? • Would you start ART with pneumocystis or cryptococcal infections?

  34. ART is often not initiated during acute opportunistic infections (OI) due to concern for: • immune reconstitution inflammatory syndrome (IRIS) • drug interactions IRIS - immune reconstitution inflammatory syndrome: - Recovery of immune reactivity can result in symptoms - worsening or unmasking of M. tuberculosis - increased mortality from Cryptococcus - zoster - worsening vision with CMV retinitis - worsening of multifocal leukoencephalopathy - Corticosteroids may diminish symptoms Adjusting for co-administration with rifampicin: - Nevirapine (and efavirenz) concentrations decreased - Virologic suppression of EFV-ART unaffected, NVP-ART inferior Boulle et al. JAMA 2008;300: 530-9 - Kaletra (LPV/rt (4:1)), when modified to LPV/rt (1:1) - AUC ~50% less with rifampicin - Cmin similar with and without rifampicin Ren et al. JAIDS 2008;47:566-9- - Rifabutin does not induce cytochrome P-450, thus, preferred, but costly

  35. Randomized trial of ART initiated during or after acute opportunistic infections (OI) – (MTB-excluded) • Study design to assess time to start ART when treating OI: • ART given within 14 days of treating OI vs ART deferred to after OI • Stratified by opportunistic infections and CD4 (< or ≥50 cells/mm3) • Tuberculosis excluded (evaluated in a separate ongoing study) • ART = lopinavir/ritonavir (LPV/r), stavudine (d4T), tenofovir/emtricitabine (TDF/FTC) • Outcomes:  death or AIDS progression; no progression and HIV viral load ≥50; or no progression and viral load <50 copies/mL • Results (Feb 2008) • 141 patients were randomized to each arm (immediate vs. deferred ART). • OI: Pneumocystic carinii pneumonia (PCP) 63%, cryptococcal meningitis 13%, pneumonia 10%, and 30% had more than one OI identified at entry • Immediate ART - median of 12 (range 9-13 days); deferred ART - 45 (range 41-55) days • No statistically significant difference in the primary endpoint:  • 14% vs 24% for death or AIDS progression • 38% vs 31% for no progression and HIV viral load ≥50 copies/mL • 48% vs 45% for no progression and viral load <50 copies/mL • However, immediate ART had:  • Fewer deaths/AIDS progressions (20 vs. 34, p = 0.035) • Longer time to death/AIDS progression (stratified HR = 0.53, p = 0.02) • Faster increase in CD4 counts to >50 and >100 cells/uL • A  Randomized Strategy Trial, ACTG 5164, CROI 2008, (abstr. 142)

  36. Percentage of people on treatment who are children, by country, 2005 Latin America and Caribbean[Median: 8%] Africa[Median: 7%] Panama Honduras UR Tanzania Argentina Uganda Haiti Ctr African Republic Guyana Zambia Brazil South Africa El Salvador Kenya Venezuela Zimbabwe Peru Namibia Rwanda 0% 2% 4% 6% 8% 10% 12% 14% 16% Mozambique Malawi Asia[Median: 4%] Côte d'Ivoire Nigeria Cambodia Ghana Viet Nam India 0% 2% 4% 6% 8% 10% 12% 14% 16% China 0% 2% 4% 6% 8% 10% 12% 14% 16% Source: WHO/UNAIDS (2005). Progress on global access to HIV antiretroviral therapy: An update on “3 by 5.” 7.3 Source: WHO/UNAIDS (2005). Progress on global access to HIV antiretroviral therapy: An update on "3 by 5."

  37. Individuals Receiving Needed Antiretroviral Therapy (ART) in Low- and Middle-Income Countries with More Than 25% “Coverage“ in June 2006. Coverage generally lower in children due to: - delayed diagnosis - fewer children, less public health concern - complex dosing / scarcity of liquid medicines Steinbrook R. NEJM 2006;355:1081

  38. $$$ $$$ $$$ $$$ $$$ $$$ Goal of Antiretroviral Treatment: Balance Benefits vs. Risks 1. Suppress plasma virus to <50c/uL - persistent CD4+ cell gain 2. Minimize inconvenient, poorly-tolerated or toxic ART 3. Sustainable program within public health system • Programs with long-term efficacy are costly: • Test for drug-resistance in newly diagnosed, +/- ART-failure • Quantification of plasma HIV-1 RNA and CD4 • Provide “new” antiretrovirals, without cross-resistance

  39. Thank you for your attention. Questions?

  40. M184V + thymidine analog mutations M184V only or wild-type Mutations Accumulate During Virologic Failure of AZT/3TC/ABC Increasing NRTI cross-resistance Subjects (%) 9-16 (n = 39) (n = 24) (n = 20) (n = 34) (n = 28) (n = 16) Weeks On Therapy After First Genotype Test CNA3005. Melby T et al. 8th CROI, Chicago, 2001. Abstract 448

  41. Next session: January 22, 2009 Listserv: itechdistlearning@u.washington.edu Email: DLinfo@u.washington.edu

  42. Next session: November January 22, 2009 Roy Colven, MD HIV Dermatology: Virtual Office Hours: Cases from India

More Related